The Connecticut State Medical Examining Board recently reprimanded two surgeons, one in Norwich, and one in New Haven, for medical errors during surgeries.
In January 2008, at William W. Backus Hospital, Dr. Gregory Criscuolo of Norwich performed spinal surgery intended to alleviate an impinged nerve in a patient’s spine. Dr. Criscuolo removed the wrong lamina, part of the vertebra. After realizing his mistake, he operated on the correct site.
On Monday, the FDA initiated a recall of various chocolate products manufactured by Chocolate Decadence after a Connecticut consumer became ill from eating the chocolate.
Subsequent investigation revealed that the chocolate had been manufactured on production lines that had previously been used to process milk chocolate. It was thus determined that the products contain an undeclared milk allergen. Consumers who are allergic to milk run the risk of serious or life-threatening reaction if they consume these products.
According to the FDA release, the recalled products were distributed nationwide via the Internet and physical retail locations.
While showering with her two young female children on July 23, 2011, in a bathroom facility at Hammonassett State Park, a Young Woman noticed that they were being watched from behind the shower through holes. Subsequently, two men, state workers, were arrested and admitted their conduct. This conduct was invasive and insulting to my Client and also outraged her husband who witnessed the impact that this had upon his wife. The conduct appears legally actionable as it did subject the victims who were enjoying their family vacation time to extreme emotional and mental distress stemming from this invasion of their privacy.
We recently blogged about cases of neglect at Connecticut nursing homes.
The New Haven Independent reported last Tuesday of yet another instance of poor medical care at a Connecticut nursing home. In this case, a nursing home was fined $3,000 by the State Department of Public Health after investigators determined that multiple nurses at the facility had withheld from patients medications prescribed by their physicians.
Connecticut patients being treated for wet age-related macular degeneration (AMD) with eye injections should be aware that, last week, the U.S. Food and Drug Administration (FDA) issued a release alerting health care professionals to a cluster of serious eye infections suffered by patients in Florida and Tennessee who received eye injections of repackaged Avastin (bevacizumab). Avastin is approved for treatment of various cancers, but used off-label in smaller doses by many ophthalmologists to treat wet AMD due to its substantially lower cost than alternatives ($50/dose vs. $2,000/dose for Lucentis). Tragically, some of the patients were blinded.
As explained on EyeDocNews (a blog covering new treatments for eye conditions), in order to convert Avastin from a cancer drug to a wet AMD drug, pharmacies must repackage the vials into much smaller doses. If that repackagaging process is not handled with proper aseptic techniques, product sterility can be compromised, which puts patients at risk for microbial infections.